Douglas Hogarth
Pulmonary Disease · Chicago, ILNPI 1619030137
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by AstraZeneca at 31.5% of the total. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,079 payments — averaging $937.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$908K
- Johnson & Johnson$559K
- Noah Medical Corporation$433K
- Grifols USA, LLC$247K
- Takeda Pharmaceuticals U.S.A., Inc.$176K
- Pulmonx Corporation$149K
- plus $414K from 48 others
Across 90 payments — averaging $2331.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pulmonx Corporation$66K
- Shire North American Group Inc$63K
- Gyrus ACMI, Inc.$52K
- Vertex$14K
- Spiration, Inc.$11K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- plus $675 from 1 others
What the payments were for
- Consulting fees$823,52629%
- Speaking & faculty fees$1,703,73459%
- Travel & lodging$204,2067%
- Food & beverage$86,3583%
- Education$69,1492%
- Gifts$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$581,819
- TEZSPIRE$325,356
- GALAXY$308,159
- Monarch Platform$197,346
- GLASSIA$180,933
- Prolastin-C Liquid$168,692
- ZEPHYR ENDOBRONCHIAL VALVE$139,355
- Prolastin-C$68,898
- Spiration Valve System$64,196
- CHARTIS CATHETER$48,146
- ZEPHYR DELIVERY CATHETER$48,146
- PULMONX CHARTIS TABLET CONSOLE$48,146
- GENERAL PULMONARY$42,604
- MONARCH$27,210
- STIOLTO RESPIMAT$19,247
- DUPIXENT$10,245
- superDimension$9,155
- CERTUS 140 MICROWAVE ABLATION SYSTEM$8,676
- IMFINZI$8,592
- Pulmonx Endobronchial Valve EBV$7,872
How this compares
$2,887,016 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 97 | $1,047,704 |
| GlassiaAlpha-1-Proteinase Inhibitor | 65 | $1,020,853 |
| ZemairaAlpha-1-Proteinase Inhibitor | 23 | $609,874 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 28 | $383,177 |
| Fasenra PenBenralizumab | 20 | $107,935 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $86,708 |
| TezspireTezepelumab-Ekko | 25 | $80,008 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $60,966 |
| Spiriva RespimatTiotropium Bromide | 66 | $59,130 |
| Spiriva HandihalerTiotropium Bromide | 43 | $41,091 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $24,719 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $19,139 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $18,184 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $14,963 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $13,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia, Gammagard Liquid | $176,107 | $1,081,81977 claims |
| Grifols USA, LLCProlastin C | $247,074 | $1,047,70497 claims |
| CSL BehringZemaira | $13 | $609,87423 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $4,564 | $137,708187 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $908,058 | $126,154110 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $44,539 | $71,43284 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Chicago
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
- Ajay WaghChicago$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.